Free Trial

Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals logo
GBX 1,773 -13.00 (-0.73%)
As of 12:21 PM Eastern

HIK vs. HCM, INDV, AMYT, AGY, APH, BXP, ANCR, STX, VLG, and EAH

Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Shield Therapeutics (STX), Venture Life Group (VLG), and ECO Animal Health Group (EAH). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Hikma Pharmaceuticals vs. Its Competitors

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, HUTCHMED had 1 more articles in the media than Hikma Pharmaceuticals. MarketBeat recorded 2 mentions for HUTCHMED and 1 mentions for Hikma Pharmaceuticals. HUTCHMED's average media sentiment score of 0.99 beat Hikma Pharmaceuticals' score of 0.00 indicating that HUTCHMED is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hikma Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
HUTCHMED
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Hikma Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

63.6% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 2.2% of HUTCHMED shares are held by institutional investors. 17.8% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 2.8% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.22B1.22£353.21M£1.671,061.68
HUTCHMED£602.20M3.37-£52.98M£0.53445.28

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.71% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals9.45% 12.71% 9.40%
HUTCHMED -6.87%-5.71%-5.90%

Hikma Pharmaceuticals presently has a consensus price target of GBX 2,627.50, indicating a potential upside of 48.20%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Hikma Pharmaceuticals beats HUTCHMED on 12 of the 16 factors compared between the two stocks.

Get Hikma Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIK vs. The Competition

MetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£3.93B£1.71B£6.13B£2.58B
Dividend Yield3.51%2.95%5.73%5.32%
P/E Ratio1,061.68113.0185.154,414.47
Price / Sales1.221,442.15574.61100,817.41
Price / Cash8.3410.3737.3927.90
Price / Book1.7211.3112.398.24
Net Income£353.21M£20.70B£3.32B£5.89B
7 Day Performance-4.21%-1.55%-0.24%-0.07%
1 Month Performance9.97%3.17%9.56%2.36%
1 Year Performance-11.44%9.71%71.67%139.25%

Hikma Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIK
Hikma Pharmaceuticals
3.5542 of 5 stars
GBX 1,773
-0.7%
GBX 2,627.50
+48.2%
-8.9%£3.93B£3.22B1,061.689,100
HCM
HUTCHMED
N/AGBX 238.75
+2.0%
N/A-19.0%£2.05B£602.20M450.471,760Positive News
INDV
Indivior
1.8438 of 5 stars
GBX 1,238
+1.6%
GBX 1,800
+45.4%
+111.6%£1.93B£1.40B-1,026.481,000News Coverage
Gap Up
High Trading Volume
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24M-4.33290Gap Down
AGY
Allergy Therapeutics
N/AGBX 7.85
-5.4%
N/A+93.8%£374.17M£55.66M-1,090.28612
APH
Alliance Pharma
1.8478 of 5 stars
GBX 64.70
flat
GBX 6,250
+9,560.0%
N/A£350.32M£183.50M-10.4391,000
BXP
Beximco Pharmaceuticals
N/AGBX 44
flat
N/A+59.6%£196.29M£46.34B3.095,500
ANCR
Animalcare Group
N/AGBX 232
-0.9%
N/A-3.1%£160.05M£81.07M6,444.44220News Coverage
STX
Shield Therapeutics
1.1251 of 5 stars
GBX 8.57
-0.3%
GBX 15
+75.0%
+65.7%£91.00M£41.50M-428.5040,000
VLG
Venture Life Group
N/AGBX 53.01
-0.9%
N/A+30.3%£67.88M£31.23M-6,975.00165Positive News
High Trading Volume
EAH
ECO Animal Health Group
N/AGBX 98.20
+4.5%
GBX 150
+52.7%
+11.4%£66.28M£79.60M4,041.15234Gap Down

Related Companies and Tools


This page (LON:HIK) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners